C4 Therapeutics, Inc. Impairment of Long-Lived Assets to be Disposed of
C4 Therapeutics, Inc. (CCCC) reported Impairment of Long-Lived Assets to be Disposed of of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2021-03-11
- C4 Therapeutics, Inc. impairment of long-lived assets to be disposed of for fiscal 2020 was $0.00.
- C4 Therapeutics, Inc. impairment of long-lived assets to be disposed of for fiscal 2019 was $0.00.
| Period end | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-11 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |